samedan logo

 
 
spacer
home > ict > summer 2007 > building consensus
PUBLICATIONS
International Clinical Trials

Building Consensus

Henry Yau at the Clinical Trials Centre, Hong Kong, rethinks the clinical trial agreement management process

Management of clinical trial agreements/contracts (CTAs) for industry-sponsored clinical trials between sponsors and study sites has been deemed a major rate-determining step for the initiation of clinical trials. Study sites are commonly blamed by the industry for their unfamiliarity with legal parlance, incomplete knowledge of legal and regulatory requirements and requests for specific arrangements that deviate from sponsors’ standard contract terms and conditions.

Sponsors, on the other hand, are condemned by study sites for using tricky and difficult-to-understand legal jargon that is biased towards sponsors and unfair to study sites. Within a sponsor's organisation, project teams frequently accuse their legal departments of wasting time on debating meaningless legalese. Legal counsels used to complain to project teams about their overlooking potential legal risks. Such conflicting views among different parties has resulted in fewer industry players attempting to look into the issue from a broader perspective and propose holistic solutions – hence the problem persists.

CTA MANAGEMENT PROCESS

Contracts are normally seen as specifically legal documents. Drafting, negotiating and managing CTAs are, therefore, commonly regarded by many sponsors, contract research organisations (CROs) and study sites as purely legal matters and the sole responsibility of legal counsels. This, however, reflects the incomplete understanding of the functions of contracts. Whilst contracts are intended to be legally binding, the primary purpose of any contract is not to take the contract parties to court, but to set out the rights and responsibilities of those parties and, ultimately, to facilitate the accomplishment of the goals of the parties under the contract. Management of CTAs is a multi-disciplinary process involving four interlocking components (see Figure 1).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
4
     

There are no comments in regards to this article.

spacer
Henry Yau has a BSc in Biochemistry and a MBA in Finance. He has 14 years’ experience in the pharmaceutical and petrochemical industries. He started his career in the pharmaceutical industry with a marketing and regulatory position in Rhone-Poulenc, and subsequently assumed a business development position in a petrochemical group. Since 2000, Henry has worked at the Clinical Trials Centre of The University of Hong Kong. Henry is currently the Assistant Director and Business Development Manager of the Clinical Trials Centre, Hong Kong, and is principally responsible for managing its strategic business development functions.
spacer
Henry Yau
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

A new anti-tumour treatment is one step closer to the clinic thanks to a new collaboration between In3Bio and 3P Biopharmaceuticals

[Pamplona, November 26 2019] 3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has been chosen by In3Bio, a UK based Biotech company, to collaborate in the development of a novel anti-tumour treatment.
More info >>

White Papers

Crunch Time: The Impact of Serialisation Requirements on Packaging Operations

PCI Pharma Services

The deadlines for including unique product identifiers on prescription drugs is putting a strain on multiple parts of the industry, much of which is ill-prepared to meet the target. Here, we look to the experience of a company that is ahead of the curve for lessons on how to manage and ease the transition to serialisation.
More info >>

 
Industry Events

ESMO Targeted Anticancer Therapies Congress 2020

2-4 March 2020, Paris, France

A unique and international mix of experts, researchers and decision makers both from academia and industry across the globe, will convene in Paris for a three-day Congress aiming at exchanging knowledge, experience and research innovations in cancer. TAT 2020 will focus, among others, on novel strategies in immuno-oncology, personalised medicine and molecular tumour boards, preclinical studies to identify effective combination therapies, use of microbiome, tumour agnostic trials, ADC technology, oncolytics, multispecific biological constructs and targeting cytokines. Participating in TAT 2020 will offer you the possibility to take part in interdisciplinary discussions inspiring new ideas and new collaborations.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement